Full-Time

Supply Chain Planning Manager

Confirmed live in the last 24 hours

Sanofi

Sanofi

10,001+ employees

Develops pharmaceuticals and vaccines globally

No salary listed

Mid, Senior

Chattanooga, TN, USA

Category
Production Planning & Scheduling
Supply Chain Management
Operations & Logistics
Required Skills
Sales
Supply Chain Management
SAP Products
Marketing
Customer Service
Requirements
  • Bachelor’s Degree required, and an MBA is a plus.
  • Desired 3-5 years’ experience in CPG/OTC Supply Chain or Materials Management preferred.
  • Knowledge of SAP and Kinaxis, or other ERP system.
  • Proficient in PC skills, especially MS Office.
  • Familiarity with FMCG, especially OTC products and key classes of trade.
  • Working knowledge of key department interactions (Production, Customer Service, Quality, Sales and Marketing).
  • Strong communication and team building skills, Must communicate “up” effectively at the Director, VP, and Sr. VP levels as well as to the shop-floor.
  • Ability to lead cross-functional teams to achieve consensus.
  • Strong problem solving and analysis skills.
  • Ability to lead projects across the E2E supply chain.
Responsibilities
  • Oversees the mid and long range rough cut capacity planning (RCCP) process.
  • Responsible for developing and analyzing capacity projects and opportunities to better utilize manufacturing capacity across all facilities.
  • Responsible for managing the twenty-four month budgetary plan and the thirty six month strategic plan.
  • Lead the E2E flow of Solid Dose supply with Global team.
  • Lead the Step 3 of the Sales and Operations Planning process, the capacity portion of the Budget and Strategic plans.
  • Provide production plans for the Long Range Plan and Budget.
  • Coordinate/lead special projects as required. Projects include, but are not limited to, analysis to support new product introductions, asset utilization studies, and supply chain optimization opportunities.
  • Work with Sales, Marketing, Operations, and Logistics to develop and maintain seasonal pre-build plans, based on manufacturing capacity and storage costs.
  • Leads business-change initiatives such as changes to the supply chain and manufacturing footprints, launches of new product lines, new distribution strategies, etc.
Desired Qualifications
  • MBA is a plus.
  • 3-5 years’ experience in CPG/OTC Supply Chain or Materials Management preferred.

Sanofi provides healthcare solutions through its pharmaceutical and biotechnology products, focusing on treatments and vaccines for various medical conditions. The company conducts extensive research and development to create new therapies and improve existing ones, particularly in areas like immunology, oncology, and rare diseases. Sanofi's products include prescription medicines, over-the-counter items, and vaccines, which are distributed to patients, healthcare professionals, and governments. What sets Sanofi apart from its competitors is its strong emphasis on scientific innovation and strategic partnerships, allowing it to maintain a diverse product pipeline. The company's goal is to enhance health outcomes and improve the quality of life for people globally by delivering effective and safe healthcare solutions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi's acquisition of Dren Bio enhances its biopharmaceutical capabilities.
  • Tolebrutinib's potential approval could revolutionize MS treatment with a novel mechanism.
  • Dupixent shows promise as a first targeted treatment for bullous pemphigoid.

What critics are saying

  • Increased competition from biosimilars threatens Sanofi's market share in key areas.
  • Geopolitical tensions in Eastern Europe may disrupt Sanofi's supply chain.
  • Scrutiny on drug pricing could pressure Sanofi's profitability.

What makes Sanofi unique

  • Sanofi's R&D focuses on unmet needs in immunology, oncology, and rare diseases.
  • The company has a robust pipeline of innovative vaccines and therapies.
  • Sanofi's global reach allows it to navigate diverse regulatory environments effectively.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

PharmiWeb
Mar 25th, 2025
Tolebrutinib Regulatory Submission Accepted For Priority Review In The Us For Patients With Multiple Sclerosis

If approved, tolebrutinib would be the first and only brain-penetrant BTK inhibitor to both treat non-relapsing secondary progressive multiple sclerosis (MS) and slow disability accumulation independent of relapse activityTolebrutinib has the potential to be the first therapy to target smoldering neuroinflammation, a key driver of disability accumulation in MSTolebrutinib was granted breakthrough therapy designation by the FDA based on positive results from the HERCULES phase 3 study in adults with non-relapsing secondary progressive MSParis, March 25, 2025. The US Food and Drug Administration (FDA) is evaluating under priority review the regulatory submission of tolebrutinib to treat non-relapsing secondary progressive multiple sclerosis (nrSPMS) and to slow disability accumulation independent of relapse activity in adult patients. The target action date for the FDA decision is September 28, 2025. A regulatory submission is also under review in the EU.The regulatory submissions in the US and the EU are supported by the results from the phase 3 studies HERCULES in nrSPMS and GEMINI 1 and 2 in relapsing MS (RMS). The findings from these studies, as well as additional clinical and preclinical studies, support the differentiated mechanism of tolebrutinib to target disability progression independent of relapse activity, and the scientific hypothesis that smoldering neuroinflammation represents a key inflammatory process in MS and is a critical driver of disability accumulation.Erik Wallström, MD, PhDGlobal Head of Neurology Development“The totality of data across our clinical program validates our scientific understanding of smoldering neuroinflammation as a distinct inflammatory process in MS. People living with non-relapsing secondary progressive multiple sclerosis or who experience disability independent of relapse activity suffer from disability that worsens over time due to persistent inflammation in the brain, known as smoldering neuroinflammation, which is the primary driver of disability

PharmiWeb
Mar 25th, 2025
Availability Of The Q1 2025 Aide Mémoire

Paris, France – March 24, 2025. Sanofi announced today that its Q1 2025 Aide mémoire is available on the "Investors" page of the company's website:First quarter 2025 (sanofi.com)As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various non-comparable items and exclusivity losses as well as the foreign currency impact and share count. Sanofi's first quarter 2025 results will be published on April 24, 2025.About SanofiWe are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.Sanofi is listed on EURONEXT: SAN and NASDAQ: SNYMedia RelationsSandrine Guendoul | + 33 6 25 09 14 25 | [email protected] Berland | + 1 215 432 0234 | [email protected] Obrist | + 33 6 77 21 27 55 | [email protected]éo Le Bourhis | + 33 6 75 06 43 81 | [email protected] Rouault | + 33 6 70 93 71 40 | [email protected] Gilbert | + 1 516 521 2929 | [email protected] RelationsThomas Kudsk Larsen | + 44 75 45 51 36 93| [email protected]é Kaisserian | + 33 6 47 04 12 11 | [email protected] Lauscher | + 1 908 612 7239 | [email protected] Browne | +1 781 249 1766 | [email protected] Pham | + 33 7 85 93 30 17 | [email protected] Elgoutni | + 1 617 710 3587 | [email protected] Châtelet | + 33 6 80 80 89 90 | [email protected] Li | + 33 6 84 00 90 72 | [email protected] statementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended

BNE
Mar 20th, 2025
Serbian biotech Dren Bio sold to Sanofi for $1.9bn

Pharma-major Sanofi has acquired Serbian-founded biopharmaceutical company Dren Bio for up to $1.9bn, the companies announced in a press release on ...

PharmiWeb
Mar 10th, 2025
Dupixent Late-Breaking Positive Pivotal Data In Bullous Pemphigoid Presented At Aad

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itchDupixent also significantly reduced oral corticosteroid and rescue medicine use compared to placeboData support the potential of Dupixent to be the first and only targeted medicine to treat bullous pemphigoid, a skin disease with underlying type 2 inflammation; regulatory submissions are under review in the US and the EUParis and Tarrytown, NY, March 8, 2025. Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent (dupilumab) in adults with moderate-to-severe bullous pemphigoid (BP) were shared in a late-breaking oral presentation at the 2025 American Academy of Dermatology (AAD) Annual Meeting. BP is a chronic, debilitating, and relapsing skin disease with underlying type 2 inflammation and characterized by intense itch and blisters, reddening of the skin, and painful lesions.Victoria Werth, MDChief of the Division of Dermatology at the Philadelphia Veterans Administration Hospital, Professor of Dermatology and Medicine at the Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center, and principal investigator of the study“People with bullous pemphigoid live with unrelenting itch, blisters, and painful lesions that can be debilitating and make it difficult to function daily. Moreover, current treatment options can be challenging for this primarily elderly patient population because they work by suppressing their immune system. By targeting the underlying type 2 inflammation, which is a key driver for bullous pemphigoid, Dupixent is the first investigational biologic to show sustained disease remission and reduce disease severity and itch compared to placebo in a clinical study.”The ADEPT study met all primary and key secondary endpoints, enrolling 106 adults with moderate-to-severe BP who were randomized to receive Dupixent 300 mg (n=53) every two weeks after an initial loading dose or placebo (n=53) added to standard-of-care oral corticosteroids (OCS). During treatment, all patients underwent a protocol-defined OCS tapering regimen if control of disease activity was maintained

Sanofi
Mar 7th, 2025
Press release: Sanofi successfully prices EUR 1.5 billion of bond issue

Sanofi successfully prices EUR 1.5 billion of bond issue  Paris, March 5, 2025. Sanofi announces that it has successfully priced its offering of EUR 1.5 billion of notes across 2 tranches: €850...